WO2002096350A3 - Immunogenic peptide composition for the prevention and treatment of alzheimer's disease - Google Patents

Immunogenic peptide composition for the prevention and treatment of alzheimer's disease Download PDF

Info

Publication number
WO2002096350A3
WO2002096350A3 PCT/US2002/010293 US0210293W WO02096350A3 WO 2002096350 A3 WO2002096350 A3 WO 2002096350A3 US 0210293 W US0210293 W US 0210293W WO 02096350 A3 WO02096350 A3 WO 02096350A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
alzheimer
disease
prevention
treatment
Prior art date
Application number
PCT/US2002/010293
Other languages
French (fr)
Other versions
WO2002096350A2 (en
Inventor
Chang Yi Wang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2002303211A priority Critical patent/AU2002303211B2/en
Priority to DK02731223.0T priority patent/DK1497313T3/en
Priority to AT02731223T priority patent/ATE474000T1/en
Priority to DE60237044T priority patent/DE60237044D1/en
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Priority to MXPA03010631A priority patent/MXPA03010631A/en
Priority to CA002448171A priority patent/CA2448171A1/en
Priority to JP2002592863A priority patent/JP4440544B2/en
Priority to EP02731223A priority patent/EP1497313B1/en
Priority to BR0210010-0 priority patent/BRPI0210010B8/en
Priority to CN028106210A priority patent/CN1568329B/en
Publication of WO2002096350A2 publication Critical patent/WO2002096350A2/en
Priority to ZA2003/08767A priority patent/ZA200308767B/en
Publication of WO2002096350A3 publication Critical patent/WO2002096350A3/en
Priority to HK05102035.8A priority patent/HK1068215A1/en
Priority to AU2008202270A priority patent/AU2008202270B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Abstract

The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid ß(Aß) peptide linked to a helper T cell epitope (Th) having multiple class II MHX binding motifs. The peptide immunogen elicit a site-directed immune response against the main functional/regulatory site of the Aß peptide and generate antibodies, which are highly cross-reactive to the soluble Aß1-42 peptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble Aß1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the 'soluble Aß-derived toxins'; and being cross-reactive to the amyloid plaques, accelerate the clearance of these plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer's Disease.
PCT/US2002/010293 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease WO2002096350A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA002448171A CA2448171A1 (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
AT02731223T ATE474000T1 (en) 2001-05-25 2002-04-02 IMMUNOGENIC PEPTIDE COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
DE60237044T DE60237044D1 (en) 2001-05-25 2002-04-02 IMMUNOGENIC PEPTIDE COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALZHEIMER DISEASE
EP02731223A EP1497313B1 (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
MXPA03010631A MXPA03010631A (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease.
DK02731223.0T DK1497313T3 (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of Alzheimer's disease
JP2002592863A JP4440544B2 (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for prevention and treatment of Alzheimer's disease
AU2002303211A AU2002303211B2 (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
BR0210010-0 BRPI0210010B8 (en) 2001-05-25 2002-04-02 peptide immunogen, as well as composition and application comprising them
CN028106210A CN1568329B (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of Alzheimer's disease
ZA2003/08767A ZA200308767B (en) 2001-05-25 2003-11-11 Immunogenic peptide composition for the prevention and treatment of alzheimers disease
HK05102035.8A HK1068215A1 (en) 2001-05-25 2005-03-08 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
AU2008202270A AU2008202270B2 (en) 2001-05-25 2008-05-22 Immunogenic peptide composition for the prevention and treatment of Alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/865,294 US6906169B2 (en) 2001-05-25 2001-05-25 Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US09/865,294 2001-05-25

Publications (2)

Publication Number Publication Date
WO2002096350A2 WO2002096350A2 (en) 2002-12-05
WO2002096350A3 true WO2002096350A3 (en) 2004-11-11

Family

ID=25345158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010293 WO2002096350A2 (en) 2001-05-25 2002-04-02 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease

Country Status (16)

Country Link
US (3) US6906169B2 (en)
EP (2) EP2123671B1 (en)
JP (3) JP4440544B2 (en)
CN (2) CN1568329B (en)
AT (2) ATE474000T1 (en)
AU (2) AU2002303211B2 (en)
BR (1) BRPI0210010B8 (en)
CA (2) CA2665748C (en)
DE (2) DE60237044D1 (en)
DK (2) DK2123671T3 (en)
ES (2) ES2360465T3 (en)
HK (2) HK1068215A1 (en)
MX (1) MXPA03010631A (en)
TW (1) TWI252233B (en)
WO (1) WO2002096350A2 (en)
ZA (1) ZA200308767B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
CN110684122B (en) * 2019-10-29 2021-03-02 中国人民解放军军事科学院军事医学研究院 Recombinant Tau epitope chimeric polymer antigen, preparation method and application thereof

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
CN1279971C (en) * 2000-02-21 2006-10-18 法麦克萨有限公司 Novel method for down-regulation of amyloid
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (en) * 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
CA2466841A1 (en) * 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20040001848A1 (en) * 2002-03-01 2004-01-01 Szu-Yi Chou Method of producing disease-specific antigens
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP4662719B2 (en) * 2002-04-19 2011-03-30 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント Immunological methods and compositions for the treatment of Alzheimer's disease
EP1911765A3 (en) * 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP4888876B2 (en) 2003-06-13 2012-02-29 田平 武 Recombinant adeno-associated virus vector for the treatment of Alzheimer's disease
EP1515158B1 (en) * 2003-09-09 2013-07-17 Esaote S.p.A. Ultrasound imaging method combined with the presence of contrast media in the body under examination
MXPA06006821A (en) 2003-12-17 2006-08-23 Elan Pharm Inc Abeta IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME.
JP2007522119A (en) * 2004-01-28 2007-08-09 キュリックス エーピーエス Conjugates of amyloid protein as vaccines for amyloid-related diseases
CU23297A1 (en) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular IMMUNOTHERAPY / 00UTICAL FORMULATIONS FOR THE INDUCTION OF BLOCKING AUTHORTIC BODIES OF THE INTERLEUCINE-2 UNION TO ITS RECEIVER. ITS USE IN THE TREATMENT OF CÃ NCER
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en) * 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
NO346055B1 (en) * 2005-12-12 2022-01-24 Ac Immune Sa Antigen design, vaccine composition and method of manufacture thereof.
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US8034353B2 (en) 2006-02-22 2011-10-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide vaccine for inducing the production of anti-amyloid β-peptide antibody
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (en) * 2006-04-21 2011-02-23 杜如昱 Human anti-Abeta(1-32) amyloid antibody, purifying method and use thereof
CA2653628C (en) 2006-06-01 2015-07-14 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
BRPI0810118A8 (en) * 2007-04-18 2015-09-29 Janssen Alzheimer Immunotherap METHOD TO TREAT DISEASE, METHOD TO EFFECT CAA PROPHYLAXIS, USE OF AN AGENT, METHOD TO REDUCE VASCULAR AMYLOID IN A PATIENT, AND, KIT FOR TREATMENT
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5349297B2 (en) * 2007-04-20 2013-11-20 一般財団法人化学及血清療法研究所 Method for enhancing peptide immune response
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
EP2106802A1 (en) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modified peptides as synthetic vaccines in amyloid-associated disease
JP5559789B2 (en) * 2008-08-07 2014-07-23 マーシア・ファーマ・インコーポレイテッド Immunotherapeutic composition for the treatment of Alzheimer's disease
US20110256172A1 (en) * 2008-10-14 2011-10-20 The Regents Of The University Of Michigan Epitope-targeted anthrax vaccine
JP5474807B2 (en) 2008-10-16 2014-04-16 一般財団法人化学及血清療法研究所 Modified amyloid β peptide
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DE102008037564A1 (en) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Composition for the production of anti-amyloid beta-peptide antibodies with D-peptides
CN106390107B (en) 2009-06-10 2019-12-31 纽约大学 Immune targeting of pathological TAU proteins
US20110221240A1 (en) * 2010-03-11 2011-09-15 Ziming Shen Compact children's table and stool set
KR101675185B1 (en) 2010-07-08 2016-11-10 유나이티드 바이오메디칼 인크. Designer peptide-based pcv2 vaccine
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN102775478B (en) * 2012-08-10 2013-06-19 申联生物医药（上海）有限公司 Foot and mouth disease virus antigen peptide and vaccine
WO2014031697A2 (en) * 2012-08-21 2014-02-27 The Institute Of Molecular Medicine COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
TWI609026B (en) * 2014-03-14 2017-12-21 美國聯合生物醫學公司 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
US20210138049A1 (en) * 2017-06-16 2021-05-13 United Neuroscience Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
BR112020008202A2 (en) * 2017-10-27 2020-10-27 United Neuroscience tau peptide immunogen constructs
CN111565801B (en) * 2017-12-31 2023-11-10 美国联合生物医学公司 Peptide immunogens targeting membrane-bound IgE for the treatment of IgE-mediated allergic diseases and dosage forms thereof
AU2019262609A1 (en) * 2018-05-04 2020-12-03 Ubi Ip Holdings Artificial promiscuous T helper cell epitopes that facilitate targeted antibody production with limited T cell inflammatory response
WO2020072428A1 (en) * 2018-10-01 2020-04-09 United Neuroscience Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72
CN113603773B (en) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 Monoclonal antibody 7B8 targeting amyloid protein, hybridoma cell strain secreting antibody and application
AU2022337284A1 (en) * 2021-09-01 2024-03-21 Vaxxinity, Inc. Methods for the prevention and treatment of synucleinopathies
CN116063447B (en) * 2022-09-13 2023-11-03 北京湃德智健科技有限公司 Antigen polypeptide for detecting ADAP autoantibody and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028412A1 (en) * 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1999027944A1 (en) * 1997-12-02 1999-06-10 Neuralab Limited Prevention and treatment of amyloidogenic disease
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
WO2001018169A2 (en) * 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE153534T1 (en) 1990-04-27 1997-06-15 John Mcmichael METHOD AND COMPOSITION FOR TREATING CNS DISEASES CAUSED BY ABNORMAL BETA-AMYLOID PROTEIN
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
CA2161445C (en) * 1993-04-27 2009-06-30 Anna Efim Ladd Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
WO1995011998A1 (en) 1993-10-26 1995-05-04 United Biomedical, Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ES2275570T3 (en) 1999-12-08 2007-06-16 Intellect Neurosciences, Inc. BETA CHEMERIC AMYLOID PEPTIDES.
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5843446A (en) * 1993-04-27 1998-12-01 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994028412A1 (en) * 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
WO1999027944A1 (en) * 1997-12-02 1999-06-10 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
US6228987B1 (en) * 1998-06-20 2001-05-08 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
WO2001018169A2 (en) * 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BARD F. ET AL: "Peripherally administered antibodies against amyloid beta- peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease", NATURE MEDICINE, vol. 6, no. 8, August 2000 (2000-08-01), pages 916 - 919, XP002227088 *
BEHROUZ N. ET AL: "An antiserum to the N-terminal subsequence of the Alzheimer amyloid beta protein does not react with neurofibrillary tangles", JOURNAL OF GERONTOLOGY, vol. 44, no. 6, 1989, pages B156 - B159, XP002982067 *
FRENKEL D. ET AL: "Generation of auto-antibodies towards Alzheimer's disease vaccination", VACCINE, vol. 19, no. 17-19, March 2001 (2001-03-01), pages 2615 - 2619, XP004231088 *
FRENKEL D. ET AL: "Immunization against Alzheimer 's.beta.- amyloid plaques via EFRH phage administration", PNAS, vol. 97, no. 21, October 2000 (2000-10-01), pages 11455 - 11459, XP002180061 *
GLENNER G.G. AND C.W. WONG: "Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 122, no. 3, August 1984 (1984-08-01), pages 1131 - 1135, XP002982069 *
HANAN E. AND SOLOMON B.: "Inhibitory Effect Of Monoclonal Antibodies On Alzheimer's Beta-Amyloid Peptide Aggregation", INT. J. EXP. CLIN. INVEST., vol. 3, 1996, pages 130 - 133, XP002911323 *
JANUS C. ET AL: "Abeta peptide immunization reduces behavioral impairment and plaques in a modelof Alzheimer's disease", NATURE, vol. 408, December 2000 (2000-12-01), pages 979 - 982, XP002969677 *
MAJOCHA R.E. ET AL: "Development of a monoclonal antibody specific for beta/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy", JOURNAL OF NUCLEAR MEDICINE, vol. 33, no. 12, December 1992 (1992-12-01), pages 2184 - 2189, XP002982062 *
MORGAN D. ET AL: "Abeta peptide vaccination prevents memory loss in an animal m odel of Alzheimer's disease", NATURE, vol. 408, December 2000 (2000-12-01), pages 982 - 985, XP002266055 *
SCHENK D. ET AL: "Immunization with amyloid-beta attenuates Alzheimer -disease-like pathology in the PDAPP mouse", NATURE, vol. 408, July 1999 (1999-07-01), pages 173 - 177, XP002942852 *
SOLOMON B. ET AL: "Disaggregation of Alzheimer Beta-amyloid by Site-Directed MAB", PNAS, vol. 94, April 1997 (1997-04-01), pages 4109 - 4112, XP002911322 *
SOLOMON B. ET AL: "Monoclonal Antibodies Inhibit In Vitro Fibrillar Aggregation Of The Alzheimer Beta-Amyloid Peptide", PNAS, vol. 93, January 1996 (1996-01-01), pages 452 - 455, XP002942850 *
SOLOMON B.: "The Amino Terminus of the Beta-Amyloid peptide contains an essential epitope for maintaining its solubility", PROGRESS IN ALZHEIMER'S AND PARKINSON'S DISEASES, BY FISHER, 1998, pages 205 - 211, XP002982083 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN110684122B (en) * 2019-10-29 2021-03-02 中国人民解放军军事科学院军事医学研究院 Recombinant Tau epitope chimeric polymer antigen, preparation method and application thereof

Also Published As

Publication number Publication date
EP1497313A2 (en) 2005-01-19
US20110070255A1 (en) 2011-03-24
BRPI0210010B1 (en) 2018-03-20
CN1568329A (en) 2005-01-19
EP1497313A4 (en) 2005-11-16
CA2665748C (en) 2014-01-21
US8232373B2 (en) 2012-07-31
HK1068215A1 (en) 2005-04-22
MXPA03010631A (en) 2004-09-13
WO2002096350A2 (en) 2002-12-05
JP2009221213A (en) 2009-10-01
US6906169B2 (en) 2005-06-14
CN101372511A (en) 2009-02-25
JP4440544B2 (en) 2010-03-24
DE60237044D1 (en) 2010-08-26
AU2008202270A1 (en) 2008-06-12
EP1497313B1 (en) 2010-07-14
ATE496937T1 (en) 2011-02-15
US20030068325A1 (en) 2003-04-10
US20040247612A1 (en) 2004-12-09
BRPI0210010B8 (en) 2021-05-25
JP2005506311A (en) 2005-03-03
DE60239093D1 (en) 2011-03-10
ES2360465T3 (en) 2011-06-06
JP2009227683A (en) 2009-10-08
CA2665748A1 (en) 2002-12-05
TWI252233B (en) 2006-04-01
EP2123671A1 (en) 2009-11-25
CN101372511B (en) 2012-12-26
HK1127898A1 (en) 2009-10-09
ZA200308767B (en) 2005-09-28
ATE474000T1 (en) 2010-07-15
JP5300593B2 (en) 2013-09-25
AU2008202270B2 (en) 2010-06-17
JP5300592B2 (en) 2013-09-25
CN1568329B (en) 2013-07-17
DK2123671T3 (en) 2011-05-02
BR0210010A (en) 2005-10-25
AU2002303211B2 (en) 2008-02-28
DK1497313T3 (en) 2010-10-25
EP2123671B1 (en) 2011-01-26
CA2448171A1 (en) 2002-12-05
US7951909B2 (en) 2011-05-31
ES2348975T3 (en) 2010-12-20

Similar Documents

Publication Publication Date Title
WO2002096350A3 (en) Immunogenic peptide composition for the prevention and treatment of alzheimer's disease
AU2006326283B2 (en) Therapeutic vaccine
BG66083B1 (en) Pharmaceutical compositions containing antibodies, and antibodies for prevention andf treatment of amyloidogenic disease
IL164643A (en) Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease
WO2001039796A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2002096937A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
HUP0303173A2 (en) Modified anti-egfr antibodies with reduced immunogenicity
WO2006121656A3 (en) Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
MXPA02008616A (en) Vaccine.
BG104562A (en) Composition and method for prevention and treatment of amyloidogenic disease
JP2009520758A5 (en)
WO2003051374A3 (en) SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
WO2003020765A3 (en) Vaccine therapies and prophylactic treatments of atherosclerotic diseases
WO2002035987A3 (en) METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
EP0955366A4 (en) Antigenic protein originating in malassezia
WO2004080375A3 (en) Vaccine therapy of atherosclerosis
KR880001703A (en) Active Immune Components useful for Schistosomiasis, Immunological Compositions thereof, and Methods for Making the Same
RU2353389C2 (en) Therapy of alzheimer's disease with using amyloid-beta peptide antibodies, and mixtures thereof
HUP0201410A2 (en) Compositions of a-betha peptide and processes for producing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003/08767

Country of ref document: ZA

Ref document number: 200308767

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 01894/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002303211

Country of ref document: AU

Ref document number: PA/a/2003/010631

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002731223

Country of ref document: EP

Ref document number: 2448171

Country of ref document: CA

Ref document number: 2002592863

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028106210

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002731223

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0210010

Country of ref document: BR